Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

B cell-orchestrated tolerization of T cell-dependent B cell-mediated autoimmune diseases

Project description

B cell-mediated thymic tolerance in central nervous system autoimmunity

The thymus educates T cells to distinguish between self and non-self, a process known as thymic tolerance. Failure of this mechanism can cause severe autoimmune diseases affecting the central nervous system such as neuromyelitis optica spectrum disorder, which is associated with inflammation and damage to optic nerves and spinal cord. The ERC-funded Breaking Bad project will investigate a newly discovered layer of thymic tolerance mediated by B cells, which present autoantigens such as aquaporin-4. Researchers will utilise genetic tools to track T cell fate and explore the autoimmune pathways. Results may transform understanding of central nervous system autoimmunity and assist in the design therapies for both autoimmune and neurodegenerative disorders.

Objective

Failure of thymic tolerance may result in severe autoimmune diseases that target the central nervous system (CNS), including Multiple Sclerosis (MS), Myelin Oligodendrocyte Glycoprotein (MOG)-associated Disease (MOGAD), and Neuromyelitis Optica Spectrum Disorders (NMOSD). Recently, we discovered a new layer of thymic tolerance in that thymic B cells get licensed to present activation-induced autoantigens, among them AQP4 (the target antigen in NMOSD). Thymic B cells are necessary and sufficient to purge the T cell repertoire of AQP4-specific clones.

In BREAKING BAD, we will investigate in depth how thymic B cells shape the AQP4-specific T cell repertoire by either deleting AQP4-specific conventional T cells or agonist-selecting Foxp3+ Treg cells. To understand B cell-intrinsic and extrinsic checkpoints of this process, we will use genetic means to disrupt thymic tolerance to AQP4. Since we have cloned a variety of AQP4-specific TCRs, we are now in the position to track fate decisions and functional phenotypes of naïve T cells that react against AQP4, which is – in contrast to MOG – not only expressed in the CNS but also in peripheral organs. Finally, our data indicate that amyloid precursor protein (APP), associated with cerebral amyloid angiopathy and Alzheimer's disease, is an autoantigen that is – very similar to AQP4 – induced in B cells upon CD40 stimulation and expressed in thymic B cells. Therefore, we will investigate the APP-specific T cell repertoire and its ability to provide T cell help for the generation of anti-amyloid Abeta antibodies upon disruption of B cell-mediated tolerance to Abeta peptides by conditional genetic ablation of APP in B cells.

In summary, BREAKING BAD will explore the significance of B cell-mediated tolerance for CNS autoantigens. We anticipate that our experiments will revolutionize the understanding and perhaps potential treatment options of CNS autoimmunity but also of major degenerative disorders like Alzheimer's disease.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-ADG

See all projects funded under this call

Host institution

KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
Net EU contribution
€ 2 373 592,00
Address
ISMANINGER STRASSE 22
81675 Muenchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)